Company intelligence / Profile preview

Bioceltech Therapeutics, Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Clinical trials of both autologous and HLA-haploidentical allogenic CAR-T therapies targeting CD19 (for R/R B-ALL) and CD7 (for R/R T-LBL) are ongoing. Early results include successful treatment of pediatric leukemia patients with durable remissions. The company claims internationally leading outcomes in some cases, but no pivotal trial results have been published.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyImmunotherapy
Industry: Biotech

Drug pipeline

3 assets

CD47-CAR-T cells (B6H12 scFv)

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Institute Of Hematology, Peking University People's Hospital

Beyond the preview

Go deeper on Bioceltech Therapeutics, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioceltech Therapeutics, Ltd..

Explore the full profile